

VBC Release Highlights

August 25, 2023

Practice InsightsSM is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS) and Enhancing Oncology Model (EOM).

MIPS Quality Measures Dashboard

The dashboard has been updated to reflect the below refinement(s) for:

NOTE: Table continues on the next page.

Measure	Update	Practice Impact
<p>MIPS 226: Tobacco Screening and Cessation</p>	<p>The measure has been updated to reflect the following changes:</p> <ul style="list-style-type: none"> • Denominator Exclusion: Excluding patients in hospice care for any part of the measurement period. • Denominator Exceptions have been removed for 2023. <p>Population 2</p> <p>The numerator evaluates patients receiving tobacco cessation intervention during the measurement period or in the six months prior to the measurement period.</p> <p>Population 3</p> <p>The numerator evaluates patients who were screened for tobacco use at least once during the measurement period AND who received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period if identified as a tobacco user.</p>	<p>Practices will notice an impact in the numerator, denominator, and performance due to the specification updates. The updates will impact Population 2 the least which is the population scored by CMS.</p>

Dashboard Updates

To support practices participating in the Enhancing Oncology Model (EOM), we are introducing the EOM Eligibility Dashboard to identify patients for enrollment.

To support VBC programs, we are introducing the VBC Navigation Summary dashboard, which will replace the report practices received every Tuesday through SFTPs. It also summarizes EOM episodes for patients enrolled in the model.

EOM Eligibility Dashboard

This dashboard includes patients who have a scheduled encounter within the next 2 weeks or 1 week prior who have been on chemo or hormonal therapy in the past.

This dashboard's main purpose is to provide a list of patients eligible for the EOM program that your practice can target for enrollment.

This dashboard also provides additional clinical information, such as patient diagnosis, chemo or hormone therapy names, hospice status, an end-stage renal disease flag, and primary and secondary payer information.

Use the filters across the top (callouts 1-5) to narrow down the search results by:

- Practice Name
- Division
- Location
- Provider
- High Potential EOM Candidate

EOM Eligibility Report

Practice Name: Alpha Oncology | Division: MedDiv | Location: (All) | Provider: (All) | High Potential EOM Candidate: (All)

First Name	Last Name	High Potential EOM Candidate	Age	MRN	Inclusion Criteria	Provider	Location	EOM Patient Status	EOM Patient Termed Reason	Medicare Flag	Primary Insurance	Secondary Insurance	Railroad Flag	Diagnosis Name	ICD9 Code	ICD10 Code	Possible Hospice	Possible ESRD
AAAROND	wFBJ	Yes	78	MRN44301	ORAL, VISIT	Sahou, Swastik	Others			MEDICARE	Medicare Part B Virginia/Po Box 100190	Ticare For Life WPS / Po Box 7890		Metastasis from malignant tumor of prostate (disorder)		C61		
aBImeFag	wPVL	No	48	MRN20324	IV, VISIT	Patel, Ash	Boulder Clinic			MEDICARE	Aetna / Po Box 981107	Aligna Health Aetna Medicare / Po Box 981106		Secondary malignant neoplasm of lymph node (disorder)		C77.9		
aoDKwOE	Frubs	No	66	MRN41666	IV, ORAL, VISIT	Howard, Andrea	San Francisco Medical Oncology			MEDICARE	Anthem Bbs Of Virginia/Po Box 27461	Medicare Part B Virginia/Po Box 100190		Secondary malignant neoplasm of bone (disorder)		C79.51		
aoDlhOZ	GweVC	No	75	MRN21476	IV, VISIT	Sahou, Swastik	Others			MEDICARE	Medicare Part B Virginia/Po Box 100190	Aarp Medicare Supplement Plans / Po Box 740819		Secondary malignant neoplasm of bone (disorder)		C79.51		

The dashboard will display the Patient Count based on your filters (callout 6). You may export this data by clicking the Export Patient Data button (callout 7).

6 Patient Count: 4,868 | **7 Export Patient Data**

Railroad Flag	Diagnosis Name	ICD9 Code	ICD10 Code	Possible Hospice	Possible ESRD	Date of Death	Last Visit	Next Visit	Oral Regimen	Oral Reg Start Date	Oral Reg Stop Date	Oral Drug	IV Regimen	IV Drug
	Metastasis from malignant tumor of prostate (disorder)		C61					8/10/2023	abiraterone + Prednisone Q300 (steroid), Cabazitaxel-resistant)	10/13/2022	9/8/2023	abiraterone acetate, 07/10/2023		
	Secondary malignant neoplasm of lymph node (disorder)		C77.9				8/1/2023						Carboplatin + Paclitaxel + XRT Q7D (Esophageal, Gastric), 02/21/2023	Carboplatin, 07/25/2023
	Secondary malignant neoplasm of bone (disorder)		C79.51				8/2/2023		Lenalidomide 01:14 + Bortezomib 01:4,8,11 + Saccharin/sucrose (BYD) Q21D (Primary Therapy)	3/13/2023	8/2/2023	Lenalidomide, 08/02/2023	Lenalidomide 01:14 + Bortezomib 01:4,8,11 + Desamethasone (BYD) Q21D (Primary Therapy), 02/13/2023	Bortezomib, 07/26/2023
	Secondary malignant neoplasm of bone (disorder)		C79.51				8/2/2023					Fam-Trastuzumab Deruxtecan-mkl (5.4 mg/kg) Q21D, 03/07/2023	Fam-trastuzumab deruxtecan-mkl, 03/11/2023	
	Secondary malignant neoplasm of bone (disorder)		C79.51				8/7/2023	8/9/2023				Fulvestrant, 07/11/2023	Fulvestrant 0280, 04/06/2022	Fulvestrant, 07/11/2023

This will open the Download Crosstab window. Select the Patient Data option (callout 8), choose your preferred document format (callout 9), and click the Download button (callout 10) to complete the data export.

NOTE: Choose the CSV format for the most optimal experience. If you choose Excel, save the file as a CSV to ensure the most accurate information.

Download Crosstab ×

Select a sheet from this dashboard

8

*Patient Data DO NOT EXP... DO NOT EXP... EOM Eligibilit... Filters

Select Format **9**

Excel CSV

10 Download

VBC Navigation Summary Dashboard

The dashboard data is based on the VBC Care Plan in iKnowMedSM Generation 2. It will replace the report practices received every Tuesday through SFTP. It will include VBC Programs documented in the VBC Care plan with the ability to filter by program.

In addition, this dashboard includes the following EOM information: episode, EOM PBPM fee, MEOS date of service, location, provider, diagnosis, episode start date, episode end date, billing date of service, billing fees, last modified, users, and comments.

Use the filters across the top (callouts 1-5) to narrow down the search results by:

- Practice Name
- Division
- Location
- Provider
- VBC Program


VBC Navigation Summary

Practice ¹ [Alpha Oncology] |
 Division ² [NoDiv] |
 Location ³ [(All)] |
 Provider ⁴ [(All)] |
 VBC Program ⁵ [(All)] |
 Report Date ⁶ [8/7/2023]

Enhancing Oncology Model Status

Provider	Enhancing Oncology Model Patients	Non-Enhancing Oncology Model Patients	Total Patients
Deslouches, Elijah	174	212	386
Howard, Andrea	238	587	825
Patel, Ash	140	385	525
Sahoo, Swastik	192	621	813
Grand Total	744	1,787	2,531

The VBC Program option filters the table by the programs documented for your patients in iKnowMed Generation 2:



The dashboard will display patient-level details based on your filters. You may export this data by clicking the Export Patient Data button (callout 6).

EOM Status | Patient Level Details | All Provider Data

VBC Navigation Summary EOM Patient Counts All Provider Data

Practice [Alpha Oncology] | Division [NoDiv] | Location [All Locations] | Provider [All Providers] | VBC Program [All Programs] | Report Date [8/7/2023]

Patient Level Details Export Patient Data ⁶


First Name	Last Name	MRN	Age	Diagnosis	Program Name	Provider	Division	Location	Episode Number
aaGYDGkH	hxttI	MRN97566	58	Non-small cell lung cancer (disorder)	Virginia Premier Oncology Episodes of C...	Howard, Andrea	NoDiv	San Francisco Medical Oncology	
aBqqInrV	vidfZ	MRN21285	68	Breast cancer, female	Anthem Oncology Medical Home Plus	Howard, Andrea	NoDiv	San Francisco Medical Oncology	
ACmNijR	xQMRW	MRN93698	73	Marginal zone lymphoma of spleen (disorder)	Anthem Oncology Medical Home	Howard, Andrea	NoDiv	San Francisco Medical Oncology	

This will open the Download Crosstab window. Select the Patient Data option (callout 7), choose your preferred document format (callout 8), and click the Download button (callout 9) to complete the data export.


NOTE: Choose the CSV format for the most optimal experience. If you choose Excel, save the file as a CSV to ensure the most accurate information.

Download Crosstab
✕


Select a sheet from this dashboard




*Patient Data




DO NOT EXP...



DO NOT EXP...



DO NOT EXP...



DO NOT EXP...

Select Format 8

Excel
 CSV

Download 9

Status of Dashboard Updates for 2023

CMS releases updates to the quality measure specifications annually for the MIPS program and bi-annually for the OCM program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2023 requirements. The measures listed below either have no 2023 update required or have been updated.

NOTE: Table continues on the next page.

Measure	Description
MIPS Quality Measures Dashboard	
#047	Advance Care Plan
#104	Adjuvant Hormonal Therapy for High-Risk or Very High-Risk Prostate Cancer
#130	Current Medications Documentation
#134	Preventive Care Screening: Screening for Depression and Follow-Up Plan
#143	Pain Intensity Quantified
#144	Pain Care Plan
#226	Tobacco Screening and Cessation
#236	Controlling High Blood Pressure
#374	Closing the Referral Loop
#451	RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy
#452	Percentage of Adult Patients (aged 18 or older) with Metastatic Colorectal Cancer and RAS (KRAS & NRAS) Gene Mutation Spared Treatment with Anti-EGFR Monoclonal Antibodies
#457	Patients Admitted to Hospice for < 3 Days
PIMSH#1	Advance Care Planning in Stage 4 Disease
PIMSH#2	Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure)

Measure	Description
PIMSH#4	Patient-Reported Pain Improvement
PIMSH#8	Mutation Testing for Lung Cancer
PIMSH#9	Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH#10	Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting Drugs
PIMSH#15	Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)
PIMSH#16	Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center